{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:21:26Z","timestamp":1792552886453,"version":"4.5.0"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford\u2013AstraZeneca), a prime\u2013boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups: the CoronaVac-ChAdOx1 vaccinee (n = 155), the homologous CoronaVac vaccinee (n = 32), the homologous ChAdOx1 vaccinee (n = 47), and control group of COVID-19 patients (n = 120). Immunogenicity was evaluated by measuring the level of IgG antibodies against the receptor-binding domain (anti-SRBD) of the SARS-CoV-2 spike protein S1 subunit and the level of neutralizing antibodies (NAbs) against variants of concern (VOCs) using the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT). The safety profile was recorded by interviewing at the 1-month visit after vaccination. The anti-SRBD level after the second booster dose of the CoronaVac-ChAdOx1 group at 2 weeks was higher than 4 weeks. At 4 weeks after the second booster dose, the anti-SRBD level in the CoronaVac-ChAdOx1 group was significantly higher than either homologous CoronaVac, the homologous ChAdOx1 group, and Control group (p &lt; 0.001). In the CoronaVac-ChAdOx1 group, the PRNT50 level against the wild-type (434.5 BAU\/mL) was the highest; followed by Alpha variant (80.4), Delta variant (67.4), and Beta variant (19.8). The PVNT50 level was also found to be at its highest against the wild-type (432.1); followed by Delta variants (178.3), Alpha variants (163.9), and Beta variant (42.2), respectively. The AEs in the CoronaVac-ChAdOx1 group were well tolerated and generally unremarkable. The CoronaVac-ChAdOx1 heterologous regimen induced higher immunogenicity and a tolerable safety profile. In a situation when only CoronaVac-ChAdOx1 vaccines are available, they should be considered for use in responding to the Delta variant.<\/jats:p>","DOI":"10.3390\/vaccines10040536","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:24:42Z","timestamp":1648675482000},"page":"536","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine"],"prefix":"10.3390","volume":"10","author":[{"given":"Surakameth","family":"Mahasirimongkol","sequence":"first","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athiwat","family":"Khunphon","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oraya","family":"Kwangsukstid","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sompong","family":"Sapsutthipas","sequence":"additional","affiliation":[{"name":"Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkwan","family":"Wichaidit","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archawin","family":"Rojanawiwat","sequence":"additional","affiliation":[{"name":"National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuanjun","family":"Wichuckchinda","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiroj","family":"Puangtubtim","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warangluk","family":"Pimpapai","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakulrat","family":"Soonthorncharttrawat","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asawin","family":"Wanitchang","sequence":"additional","affiliation":[{"name":"Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-9883","authenticated-orcid":false,"given":"Anan","family":"Jongkaewwattana","sequence":"additional","affiliation":[{"name":"Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanjana","family":"Srisutthisamphan","sequence":"additional","affiliation":[{"name":"Epidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daraka","family":"Phainupong","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naphatcha","family":"Thawong","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pundharika","family":"Piboonsiri","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waritta","family":"Sawaengdee","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitiporn","family":"Somsaard","sequence":"additional","affiliation":[{"name":"Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokphon","family":"Ritthitham","sequence":"additional","affiliation":[{"name":"Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supaporn","family":"Chumpol","sequence":"additional","affiliation":[{"name":"Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadthanan","family":"Pinyosukhee","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattanawadee","family":"Wichajarn","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panadda","family":"Dhepakson","sequence":"additional","affiliation":[{"name":"Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sopon","family":"Iamsirithaworn","sequence":"additional","affiliation":[{"name":"Epidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supaporn","family":"Phumiamorn","sequence":"additional","affiliation":[{"name":"Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJMe2111165","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine","volume":"385","author":"Mulholland","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous Prime-Boost Vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_4","unstructured":"(2021, July 05). India\u2019s Coronavirus Death Toll Tops 400,000 as the Delta Variant Spreads Globally, Including in the United States\u2014The Washington Post. Available online: https:\/\/www.washingtonpost.com\/world\/2021\/07\/02\/coronavirus-latest-updates\/."},{"key":"ref_5","unstructured":"(2021, May 16). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_6","unstructured":"(2021, August 16). COVID-19 Weekly Epidemiological Update, Edition 52, 10 August 2021. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/344062."},{"key":"ref_7","unstructured":"(2021, May 16). GISAID\u2014Initiative. Available online: https:\/\/www.gisaid.org\/."},{"key":"ref_8","unstructured":"(2021, July 05). AstraZeneca to Deliver Six Million COVID-19 Vaccine Doses in THAILAND. Available online: https:\/\/www.astrazeneca.com\/country-sites\/thailand\/press-release\/astrazeneca-to-deliver-six-million-covid-19-vaccine-doses-in-thailand.html."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Sudhinaraset, N., Vongpunsawad, S., and Poovorawan, Y. (2021). Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv, Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.01.21262955v1.","DOI":"10.1101\/2021.09.01.21262955"},{"key":"ref_10","first-page":"21","article-title":"Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes","volume":"11","author":"Sampson","year":"2021","journal-title":"Bio-Protocol"},{"key":"ref_11","unstructured":"(2021, October 10). R: The R Project for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_12","unstructured":"(2021, October 10). RStudio\u2014RStudio. Available online: https:\/\/www.rstudio.com\/products\/rstudio\/."},{"key":"ref_13","unstructured":"Kassambara, A. (2021, October 10). Pipe-Friendly Framework for Basic Statistical. Available online: https:\/\/CRAN.R-project.org\/package=rstatix."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.4161\/hv.25750","article-title":"DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus","volume":"9","author":"Gil","year":"2013","journal-title":"Human Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Angkasekwinai, N., Niyomnaitham, S., Sewatanon, J., Phumiamorn, S., Sukapirom, K., Senawong, S., Mahasirimongkol, S., Toh, Z.Q., Umrod, P., and Somporn, T. (2021). The Immunogenicity and Safety of Different COVID-19 Booster Vaccination Following CoronaVac or ChAdOx1 nCoV-19 Primary Series. medRxiv, Available online: https:\/\/papers.ssrn.com\/abstract=3979665.","DOI":"10.21203\/rs.3.rs-1124837\/v1"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wanlapakorn, N., Suntronwong, N., Phowatthanasathian, H., Yorsaeng, R., Vichaiwattana, P., Thongmee, T., Auphimai, C., Srimuan, D., Thatsanatorn, T., and Assawakosri, S. (2022). Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort. Study, 1\u201310.","DOI":"10.1080\/21645515.2022.2029111"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1080\/22221751.2021.1957401","article-title":"Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_18","unstructured":"Takemori, T., Tarlinton, D., Hiepe, F., and Andreas, R.B. (2015). Cell Memory and Plasma Cell Development. Molecular Biology of B Cells, Elsevier Ltd.. [2nd ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vacharathit, V., Aiewsakun, P., Manopwisedjaroen, S., Srisaowakarn, C., Laopanupong, T., Ludowyke, N., Phuphuakrat, A., Setthaudom, C., Ekronarongchai, S., and Srichatrapimuk, S. (2021). SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients. medRxiv.","DOI":"10.1101\/2021.07.10.21260232"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1056\/NEJMc2103022","article-title":"Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization","volume":"384","author":"Wang","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"ref_24","unstructured":"Junker, D., Dulovic, A., Becker, M., Wagner, T.R., Laiser, P.D., Traenkle, B., Kienzle, K., Bunk, S., Struemper, C., and Haeberle, H. (2021). Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay. medRxiv."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gram, M.A., Nielsen, J., Schelde, A.B., Nielsen, K.F., Moustsen-Helms, I.R., Bj\u00f8rkholt S\u00f8rensen, A.K., Valentiner-Branth, P., and Emborg, A.-D. (2021). Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. medRxiv.","DOI":"10.1101\/2021.07.26.21261130"},{"key":"ref_26","unstructured":"(2021, December 18). Interim Recommendations for Heterologous COVID-19 Vaccine Schedules. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: An interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Buchan, S.A., Buchan, C., Brown, K.A., Austin, P.C., Fell, D.B., Gubbay, J.B., Nasreen, S., Schwartz, K.L., Sundaram, M.E., and Tadrous, M. (2022). Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv.","DOI":"10.1101\/2021.12.30.21268565"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Poukka, E., Baum, U., Palmu, A.A., Lehtonen, T.O., Salo, H., Nohynek, H., and Leino, T. (2021). Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland, December 2020\u2013October 2021. medRxiv.","DOI":"10.1101\/2021.11.03.21265791"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Suntronwong, N., Yorsaeng, R., Puenpa, J., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Duangchinda, T., Chantima, W., and Pakchotanon, P. (2022). COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron. medRxiv.","DOI":"10.1101\/2022.01.17.22269415"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/536\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:46:34Z","timestamp":1760136394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["vaccines10040536"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10040536","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.05.21264700","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]}}}